UPDATE: Imperial Capital Downgrades Rotech Healthcare; Lowers PT

According to a research report published this morning, Imperial Capital has downgraded Rotech Healthcare ROHI from Outperform to In-Line, and lowered PT from $2 to $1. In the report, Imperial Capital said, "At current levels, we believe Rotech shares are effectively trading with option value should the company manage its future Medicare cuts and/or be acquired/merge with a national competitor. Our view is supported by management's historical ability to respond to operational and reimbursement challenges." Rotech Healthcare is currently trading at $0.64.